טוען...

A novel mitochondrial inhibitor blocks MAPK pathway and overcomes MAPK inhibitor–resistance in melanoma.

PURPOSE: To determine if inhibition of mitochondrial oxidative phosphorylation (OxPhos) is an effective strategy against MAPK pathway inhibitor (MAPKi)-resistant BRAF-mutant melanomas. EXPERIMENTAL DESIGN: The anti-melanoma activity of IACS-010759 (OPi), a novel OxPhos complex I inhibitor, was evalu...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Clin Cancer Res
Main Authors: Vashisht Gopal, Y. N., Gammon, Seth, Prasad, Rishika, Knighton, Barbara, Pisaneschi, Federica, Roszik, Jason, Feng, Ningping, Johnson, Sarah, Pramanik, Snigdha, Sudderth, Jessica, Sui, Dawen, Hudgens, Courtney, Fischer, Grant M., Deng, Wanleng, Reuben, Alexandre, Peng, Weiyi, Wang, Jian, McQuade, Jennifer L., Tetzlaff, Michael T., Di Francesco, Maria E., Marszalek, Joe, Piwnica-Worms, David, DeBerardinis, Ralph J., Davies, Michael A.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2019
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6825560/
https://ncbi.nlm.nih.gov/pubmed/31439581
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0836
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!